Skip to main content

Mind Medicine (MindMed) Inc.

For the period ended Jun 30, 2025. Filed Jul 31, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 31, 2025

DFTX$34.64-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

Three Months Ended June 30,Six Months Ended June 30,
(in thousands, except share and per share amounts)2025202420252024
Operating expenses:
Research and development$29,809$14,645$53,166$26,350
General and administrative11,0949,81319,89620,312
Total operating expenses40,90324,45873,06246,662
Loss from operations(40,903)(24,458)(73,062)(46,662)
Other income/(expense):
Interest income2,7743,1165,2074,772
Interest expense(2,338)(466)(2,940)(900)
Foreign exchange loss, net(49)(32)(68)(557)
Change in fair value of 2022 USD Financing Warrants(2,228)13,4454,771(19,448)
Gain on extinguishment of contribution payable—2,541—2,541
Total other income/(expense)(1,841)18,6046,970(13,592)
Net loss(42,744)(5,854)(66,092)(60,254)
Other comprehensive loss
Unrealized gain on investments36—46—
Gain/(loss) on foreign currency translation(31)(3)(58)490
Comprehensive loss$(42,739)$(5,857)$(66,104)$(59,764)
Net loss per common share, basic$(0.50)$(0.08)$(0.78)$(1.01)
Net loss per common share, diluted$(0.50)$(0.26)$(0.81)$(1.01)
Weighted-average common shares, basic85,347,67771,912,32385,208,53959,886,540
Weighted-average common shares, diluted85,347,67775,304,10187,099,00659,886,540
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.